SEC Form SC 13G/A filed by Silk Road Medical Inc. (Amendment)
$SILK
Medical/Dental Instruments
Health Care
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/11/2024 | Buy → Sell | Argus | |
| 3/7/2024 | $24.00 | Hold → Buy | Argus |
| 1/19/2024 | $9.00 → $20.00 | Hold → Buy | Stifel |
| 1/3/2024 | $20.00 | Buy | Lake Street |
| 10/24/2023 | Underperform → Peer Perform | Wolfe Research | |
| 10/11/2023 | $54.00 → $14.00 | Buy → Neutral | B. Riley Securities |
| 10/11/2023 | Buy → Neutral | CL King | |
| 10/11/2023 | $45.00 → $12.00 | Buy → Hold | Stifel |
MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.
MARLBOROUGH, Mass., Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (NASDAQ:SILK), a medical device company that pioneered a new approach for stroke prevention and the treatment of carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). "Completing this acquisition enables Boston Scientific to strengthen our vascular technology solutions by bringing the innovative TCAR platform to a greater number of physicians and their pa
MONSEY, N.Y., Aug. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP has renewed its investigation into the fairness of the proposed sale of Silk Road Medical, Inc. (NASDAQ:SILK) ("SILK") to Boston Scientific Corporation for $27.50 per share in cash. On July 29, 2024, SILK filed a definitive proxy concerning the proposed sale with the SEC. Based on our review of the proxy, we have renewed our investigation into whether there are any undisclosed potential conflicts of interest. If you remain a SILK shareholder and question the fairness of the price or have any other concerns, you may contact our firm at the following link to discuss your legal rights at no charge: https:/
Argus downgraded Silk Road Medical from Buy to Sell
Argus upgraded Silk Road Medical from Hold to Buy and set a new price target of $24.00
Stifel upgraded Silk Road Medical from Hold to Buy and set a new price target of $20.00 from $9.00 previously
MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.
MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per share (EPS), compared to $261 million or $0.18 per share a year ago, and achieved adjusted3 EPS of $0.62 for the period, compared to $0.53 a year ago.
SUNNYVALE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2024. "Our team delivered a strong start to 2024 as we deepened relationships with the physicians we serve and continued broadening our patient impact," said Chas McKhann, CEO of Silk Road Medical. "In the first quarter, we made meaningful commercial progress while also taking steps toward sustainable profitability. We enter the second quarter feeling energized by TCAR's outstanding value proposition for physicians and patients and in our opportun
SUNNYVALE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK) ("Silk Road" or the "Company"), a company focused on reducing the risk of stroke and its devastating impact, today announced that Chas McKhann has been appointed Chief Executive Officer (CEO), effective immediately. Mr. McKhann is an accomplished leader with more than 25 years of experience in the medical device industry, including C-suite positions at seven public and private companies. Most recently, Mr. McKhann served as President and CEO of Apollo Endosurgery (acquired by Boston Scientific in April 2023), where he created and led a transformational growth strategy for the company's minimal
Working with Leading Executive Search Firm to Identify Successor SUNNYVALE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that CEO Erica Rogers plans to retire from the Company following the completion of a succession process. The Company is working with Spencer Stuart, a leading executive search firm. To ensure a smooth transition, Ms. Rogers will remain as President and CEO of the Company until her successor is appointed. "I'd like to thank Erica for her tremendous contributions to Silk Road over the last 11 years. Erica has been integral in leading and expand
SUNNYVALE, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it has appointed Dr. Tanisha Carino to its Board of Directors. Tanisha Carino, Ph.D., is a health policy expert bringing over 20 years of experience driving growth and impact across multiple healthcare leadership positions in the government, private, and non-profit sectors. She most recently served as Executive Vice President, Chief Corporate Affairs Officer of Alexion, a Fortune 500 biotechnology company focused on rare disease, which was recently acquired by AstraZeneca. Prior to Alexion, she serv
15-12G - Silk Road Medical Inc (0001397702) (Filer)
EFFECT - Silk Road Medical Inc (0001397702) (Filer)
25-NSE - Silk Road Medical Inc (0001397702) (Subject)
4 - Silk Road Medical Inc (0001397702) (Issuer)
4 - Silk Road Medical Inc (0001397702) (Issuer)
4 - Silk Road Medical Inc (0001397702) (Issuer)
4 - Silk Road Medical Inc (0001397702) (Issuer)
SC 13D/A - Silk Road Medical Inc (0001397702) (Subject)
SC 13D - Silk Road Medical Inc (0001397702) (Subject)
SC 13G/A - Silk Road Medical Inc (0001397702) (Subject)